Digital therapeutics

Last updated

Digital therapeutics, a subset of digital health, are evidence-based therapeutic interventions driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. [1] [2] [3] [4] [5] Digital therapeutic companies should publish trial results inclusive of clinically meaningful outcomes in peer-reviewed journals. [6] The treatment relies on behavioral and lifestyle changes usually spurred by a collection of digital impetuses. [3] [7] Because of the digital nature of the methodology, data can be collected and analyzed as both a progress report and a preventative measure. [8] [9] [10] [11] [12] [13] Treatments are being developed for the prevention and management of a wide variety of diseases and conditions, including type 1 & type II diabetes, congestive heart failure, obesity, Alzheimer's disease, dementia, asthma, substance abuse, ADHD, hypertension, anxiety, depression, and several others. [2] [14] [15] [16] [17] Digital therapeutics often employ strategies rooted in cognitive behavioral therapy. [18] [19] [20]

Contents

Definitions

Although digital therapeutics can be employed in numerous ways, the term can broadly be defined as a treatment or therapy that utilizes digital and often Internet-based health technologies to spur changes in patient behavior. [4] [21] The use of digital products to improve health outcomes dates as far back as 2000. [9] [3] The term itself has been in use since around 2012. [22] The first mention of the term in a peer-reviewed research publication was in 2015, in which Dr. Cameron Sepah formally defined the field as: "Digital therapeutics are evidence-based behavioral treatments delivered online that can increase accessibility and effectiveness of health care." [3] Digital therapeutics can be used as a standalone therapy or in conjunction with more conventional treatments like pharmacological or in-person therapy. [4] [18] As of 2018, digital therapeutics continues to be an evolving field that medical professionals, students, and patients are beginning to utilize. [23]

The Digital Therapeutics Alliance states: "Digital therapeutics (DTx) deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a broad spectrum of physical, mental, and behavioral conditions." [24] Digital therapeutics are different from wellness apps or medication reminders in that they require rigorous clinical evidence to substantiate intended use and impact on disease state.

It is often used as a preventive measure for patients who are at risk of developing more serious conditions. For instance, a patient with prediabetes may be prescribed digital therapeutics as a method to change their diet and behavior that could otherwise lead to a diabetes diagnosis. [3] [2] [15] [20] Digital therapeutics can also be used as a treatment option for existing conditions. For instance, a patient with type II diabetes can use digital therapeutics to manage the disease more effectively. [2] [3] [15]

The methodology uses a variety of digital implements to help manage, monitor, and prevent illnesses in at-risk patients. These include mobile devices and technologies, apps, sensors, desktop computers, and various Internet of Things devices. [25] These implements can collect a wide variety of data, ranging from big to small. Digital therapeutics can theoretically collect a high volume of data from a variety of sources. It also collects "smaller" data, "capturing personalized physiological parameters, behavior patterns and social and geographical patterns that can be recorded from multiple digital sources." [8]

Methodologies

Digital therapeutics can be used for a variety of conditions. There is no single methodology used in the practice of digital therapeutics. Many approaches use methods based upon cognitive behavioral therapy to spur patients to make lifestyle changes, reinforced with gamification, peer support, and in some cases telehealth such as coaching or psychotherapy. The method can be used to manage and improve outcomes in numerous conditions, including type II diabetes, Alzheimer's disease, dementia, congestive heart failure, chronic obstructive pulmonary disease, asthma, lung disease, obesity, substance abuse, ADHD, insomnia, hypertension, anxiety, depression, and others. [2] [16] [17] [11]

Methodologies can be as simple as psychoeducation or sending notifications designed to alter behavior to patients who are at risk of obesity or diabetes [15] [2] and as complex as administering an ingestible radio tag that communicates with an external sensor to monitor the efficacy of a given medication. [4] Diabetes and obesity prevention and management is a major focus in the field of digital therapeutics. [26] [10] Connected devices like insulin pumps, blood glucose meters, and wearable devices can all send data to a unified system. The therapy also uses self-reported data like diet or other lifestyle factors. [2] [3] It is also often used to monitor the potential for heart and lung conditions and change behaviors like smoking, poor diet, or a lack of exercise. [25] [2]

Digital therapeutics can also be used to treat patients with psychological and neurological symptoms. For example, patients with disorders like ADHD, depression, and anxiety can receive cognitive behavioral therapy via their mobile devices. [18] One study looked at the efficacy of avatar-based therapeutic interventions to reduce depressive symptoms. [14] Another study analyzed seven clinical trials to demonstrate the efficacy of a digital therapeutic in significantly reducing blood pressure. [16] A preliminary study suggested that a mobile mindfulness app may be able to decrease acute stress while improving mood. [27]

Outcomes

The general consensus among researchers in the field of digital therapeutics is that the discipline requires more clinical data and investigation to be fully evaluated. [3] [23] A variety of studies have been conducted to evaluate the efficacy and impact of behavior change techniques that utilize a digital platform, however. [3] [11] [26] In a meta-analysis of 85 such studies comprising a total sample size of over 43,000 participants, researchers discovered that digital therapeutics have a "statistically small but significant effect on health-related behavior." The study also showed that a broader use of theory, behavior change techniques, and modes of delivery (especially regular notifications) improved the efficacy of a given program. [3]

Individual studies have also showed some benefits for patients. For instance, a diabetes prevention program using digital therapeutics saw participants lose an average of 4.7% of baseline body weight after 1 year (4.2% after 2 years) and undergo a 0.38% reduction in A1c levels after 1 year (0.43% after 2 years). [3] Another weight loss pilot program using digital therapeutics reported a mean weight loss of 13.5 pounds (or 7.3% of baseline) with a significant average drop in both systolic and diastolic blood pressure (18.6 mmHg and 6.4 mmHg respectively). The study also saw a slight but statistically insignificant drop in total cholesterol, LDL, triglycerides, and A1c. [26]

That said, the concept of outcomes and impact in the context of digital therapeutics is generally defined broader than strictly health outcomes. [28] A recent review of 244 studies highlighted that, on top of improving health outcomes in certain circumstances as outlined above, the value of digital therapeutics can also arise from improving healthcare access to underserved populations and address health inequalities, or reducing healthcare expenditure. [29] This broader interpretation has also called into question the fitness of traditional health technology assessment frameworks and given rise to calls to develop novel frameworks that embrace the variety of impacts that digital therapeutics can have. [30] [31]

Regulation of digital therapeutics

While a broad range of unregulated health apps have historically been available in the App Store (iOS/iPadOS) or Google Play since their launch, many of these have been found to produce inconsistent, misleading, or dangerous results. [32] In response, regulators in the United States such as the Food and Drug Administration have developed regulatory frameworks such as software as a medical device (SaMD) [33] which require manufacturers to prove that their apps are safe, effective, and that rigorous quality management system processes are in place to ensure that remains the case as software updates occur. However, in an assessment of 4,936 apps that fall under the SaMD umbrella in the United States published in 2019, only 105 (2.13%) included a specific summary of their cybersecurity content. [34] While the content of cybersecurity in SaMD devices was observed to be growing in newer SaMD applications, the (perceived) absence of clear cybersecurity measures in the vast majority of SaMD devices remains a substantial barrier for patients and health professionals to start using digital therapeutics in practice. [29]

In the European Union, regulation (EU) 2017/745, commonly known as "EU MDR" classifies potential digital therapeutics in terms of their intended use, application, and potential to cause harm. Because digital therapeutics are increasingly operating within a regulated environment, the degree of documentation and regulatory compliance (such as ISO 13485 or the CE mark) has increased too.

Reimbursement and commercialization

Unlike medication or the billable hours of healthcare professionals, there are not currently clear pathways to reimbursement in most health systems. [33] While many manufacturers seek FDA clearance or approval, this is only the first step on the path to being reimbursed for the use of a DTX. [35] Accordingly, digital therapeutics companies pursue a range of business models:

To help build the business case for their usage, DTx companies often commission health economics evaluations of their interventions to show that their use ultimately lowers healthcare costs in the medium-long term, such as by reducing the need for hospital admissions or expensive surgeries. [35]

See also

Related Research Articles

Group psychotherapy or group therapy is a form of psychotherapy in which one or more therapists treat a small group of clients together as a group. The term can legitimately refer to any form of psychotherapy when delivered in a group format, including art therapy, cognitive behavioral therapy or interpersonal therapy, but it is usually applied to psychodynamic group therapy where the group context and group process is explicitly utilized as a mechanism of change by developing, exploring and examining interpersonal relationships within the group.

eHealth describes healthcare services which are supported by digital processes, communication or technology such as electronic prescribing, Telehealth, or Electronic Health Records (EHRs). The use of electronic processes in healthcare dated back to at least the 1990s. Usage of the term varies as it covers not just "Internet medicine" as it was conceived during that time, but also "virtually everything related to computers and medicine". A study in 2005 found 51 unique definitions. Some argue that it is interchangeable with health informatics with a broad definition covering electronic/digital processes in health while others use it in the narrower sense of healthcare practice using the Internet. It can also include health applications and links on mobile phones, referred to as mHealth or m-Health. Key components of eHealth include electronic health records (EHRs), telemedicine, health information exchange, mobile health applications, wearable devices, and online health information. These technologies enable healthcare providers, patients, and other stakeholders to access, manage, and exchange health information more effectively, leading to improved communication, decision-making, and overall healthcare outcomes.

<span class="mw-page-title-main">Personalized medicine</span> Medical model that tailors medical practices to the individual patient

Personalized medicine, also referred to as precision medicine, is a medical model that separates people into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept, though some authors and organizations differentiate between these expressions based on particular nuances. P4 is short for "predictive, preventive, personalized and participatory".

The term diabetes includes several different metabolic disorders that all, if left untreated, result in abnormally high concentrations of a sugar called glucose in the blood. Diabetes mellitus type 1 results when the pancreas no longer produces significant amounts of the hormone insulin, usually owing to the autoimmune destruction of the insulin-producing beta cells of the pancreas. Diabetes mellitus type 2, in contrast, is now thought to result from autoimmune attacks on the pancreas and/or insulin resistance. The pancreas of a person with type 2 diabetes may be producing normal or even abnormally large amounts of insulin. Other forms of diabetes mellitus, such as the various forms of maturity-onset diabetes of the young, may represent some combination of insufficient insulin production and insulin resistance. Some degree of insulin resistance may also be present in a person with type 1 diabetes.

In medicine, patient compliance describes the degree to which a patient correctly follows medical advice. Most commonly, it refers to medication or drug compliance, but it can also apply to other situations such as medical device use, self care, self-directed exercises, or therapy sessions. Both patient and health-care provider affect compliance, and a positive physician-patient relationship is the most important factor in improving compliance. Access to care plays a role in patient adherence, whereby greater wait times to access care contributing to greater absenteeism. The cost of prescription medication also plays a major role.

<span class="mw-page-title-main">Telerehabilitation</span> Delivery of rehabilitation services over the internet

Telerehabilitation (or e-rehabilitation is the delivery of rehabilitation services over telecommunication networks and the internet. Telerehabilitation allows patients to interact with providers remotely and can be used both to assess patients and to deliver therapy. Fields of medicine that utilize telerehabilitation include: physical therapy, occupational therapy, speech-language pathology, audiology, and psychology. Therapy sessions can be individual or community-based. Types of therapy available include motor training exercises, speech therapy, virtual reality, robotic therapy, goal setting, and group exercise.

In biomedical contexts, a biomarker, or biological marker, is a measurable indicator of some biological state or condition. Biomarkers are often measured and evaluated using blood, urine, or soft tissues to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Biomarkers are used in many scientific fields.

mHealth Medicine and public health supported by mobile devices

mHealth is an abbreviation for mobile health, a term used for the practice of medicine and public health supported by mobile devices. The term is most commonly used in reference to using mobile communication devices, such as mobile phones, tablet computers and personal digital assistants (PDAs), and wearable devices such as smart watches, for health services, information, and data collection. The mHealth field has emerged as a sub-segment of eHealth, the use of information and communication technology (ICT), such as computers, mobile phones, communications satellite, patient monitors, etc., for health services and information. mHealth applications include the use of mobile devices in collecting community and clinical health data, delivery/sharing of healthcare information for practitioners, researchers and patients, real-time monitoring of patient vital signs, the direct provision of care as well as training and collaboration of health workers.

The use of electronic and communication technologies as a therapeutic aid to healthcare practices is commonly referred to as telemedicine or eHealth. The use of such technologies as a supplement to mainstream therapies for mental disorders is an emerging mental health treatment field which, it is argued, could improve the accessibility, effectiveness and affordability of mental health care. Mental health technologies used by professionals as an adjunct to mainstream clinical practices include email, SMS, virtual reality, computer programs, blogs, social networks, the telephone, video conferencing, computer games, instant messaging and podcasts.

Empagliflozin, sold under the brand name Jardiance, among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes. It is taken by mouth.

Digital health is a discipline that includes digital care programs, technologies with health, healthcare, living, and society to enhance the efficiency of healthcare delivery and to make medicine more personalized and precise. It uses information and communication technologies to facilitate understanding of health problems and challenges faced by people receiving medical treatment and social prescribing in more personalised and precise ways. The definitions of digital health and its remits overlap in many ways with those of health and medical informatics.

Childhood chronic illness refers to conditions in pediatric patients that are usually prolonged in duration, do not resolve on their own, and are associated with impairment or disability. The duration required for an illness to be defined as chronic is generally greater than 12 months, but this can vary, and some organizations define it by limitation of function rather than a length of time. Regardless of the exact length of duration, these types of conditions are different than acute, or short-lived, illnesses which resolve or can be cured. There are many definitions for what counts as a chronic condition. However, children with chronic illnesses will typically experience at least one of the following: limitation of functions relative to their age, disfigurement, dependency on medical technologies or medications, increased medical attention, and a need for modified educational arrangements.

<span class="mw-page-title-main">Activity tracker</span> Device or application for monitoring fitness

An activity tracker is an electronic device, or an app on a device, that measures and collects data about an individual's movements and physical responses, towards the goal of monitoring and improving their health, fitness or psychological wellness over time.

<span class="mw-page-title-main">Health information on the Internet</span>

Health information on the Internet refers to all health-related information communicated through or available on the Internet.

Infodemiology was defined by Gunther Eysenbach in the early 2000s as information epidemiology. It is an area of science research focused on scanning the internet for user-contributed health-related content, with the ultimate goal of improving public health. Later, it is also defined as the science of mitigating public health problems resulting from an infodemic.

Joseph Antony Cafazzo is a Canadian biomedical engineer, educator, and researcher.

Digital medicine refers to the application of advanced digital technologies, such as artificial intelligence, machine learning, and big data analytics, to improve patient outcomes and healthcare delivery. It involves the integration of technology and medicine to facilitate the creation, storage, analysis, and dissemination of health information, with the aim of enhancing clinical decision-making, improving patient care, and reducing costs.

Lark Health is an American digital health company based in Mountain View, California. It provides a 24/7 nursing platform for chronic conditions, powered by artificial intelligence (AI) and has a text-messaging type interface. Lark also provides AI nurses for type 2 diabetes care, hypertension care, tobacco cessation, stress management, obesity, and more for 1.5 million patients.

<span class="mw-page-title-main">Internet-based treatments for trauma survivors</span>

Internet-based treatments for trauma survivors is a growing class of online treatments that allow for an individual who has experienced trauma to seek and receive treatment without needing to attend psychotherapy in person. The progressive movement to online resources and the need for more accessible mental health services has given rise to the creation of online-based interventions aimed to help those who have experienced traumatic events. Cognitive behavioral therapy (CBT) has shown to be particularly effective in the treatment of trauma-related disorders and adapting CBT to an online format has been shown to be as effective as in-person CBT in the treatment of trauma. Due to its positive outcomes, CBT-based internet treatment options for trauma survivors has been an expanding field in both research and clinical settings.

References

  1. ↑ "Join DTA". Archived from the original on 2020-10-28. Retrieved 2019-06-11.
  2. 1 2 3 4 5 6 7 8 Kvedar JC, Fogel AL, Elenko E, Zohar D (March 2016). "Digital medicine's march on chronic disease". Nature Biotechnology. 34 (3): 239–246. doi: 10.1038/nbt.3495 . PMID   26963544. S2CID   1515998.
  3. 1 2 3 4 5 6 7 8 9 10 11 Sepah SC, Jiang L, Peters AL (April 2015). "Long-term outcomes of a Web-based diabetes prevention program: 2-year results of a single-arm longitudinal study". Journal of Medical Internet Research. 17 (4): e92. doi: 10.2196/jmir.4052 . PMC   4409647 . PMID   25863515.
  4. 1 2 3 4 Hixon T (9 December 2015). "Digital Therapeutics Have Huge Promise And They Are Real Today". Forbes . Retrieved 19 October 2016.
  5. ↑ Cymerys E, Duffy S (May 2015). "Implementing USPSTF Recommendations on Behavioral Counseling for Cardiovascular Disease". Health Watch (78).
  6. ↑ "Understanding DTx: A New Category of Medicine" (PDF). Digital Therapeutics Alliance.
  7. ↑ Duffy S (17 April 2014). "What If Doctors Could Finally Prescribe Behavior Change?". Forbes . Retrieved 19 October 2016.
  8. 1 2 Hird N, Ghosh S, Kitano H (June 2016). "Digital health revolution: perfect storm or perfect opportunity for pharmaceutical R&D?". Drug Discovery Today. 21 (6): 900–911. doi:10.1016/j.drudis.2016.01.010. PMID   26821131.
  9. 1 2 Capobianco E (10 November 2015). "On Digital Therapeutics". Frontiers in Digital Humanities. 2 (6). doi: 10.3389/fdigh.2015.00006 .
  10. 1 2 Vlachopapadopoulou E, Fotiadis DI (26 January 2016). "Chapter 7: The Contribution of mHealth in the Care of Obese Pediatric Patients". In Moumtzoglou A (ed.). M-Health Innovations for Patient-Centered Care. IGI Global. pp. 126–146. ISBN   978-1466698611.
  11. 1 2 3 Dahlberg LE, Grahn D, Dahlberg JE, Thorstensson CA (June 2016). "A Web-Based Platform for Patients With Osteoarthritis of the Hip and Knee: A Pilot Study". JMIR Research Protocols. 5 (2): e115. doi: 10.2196/resprot.5665 . PMC   4912680 . PMID   27261271.
  12. ↑ Wicklund E (13 October 2016). "Is Digital Therapeutics the Next Big Thing in mHealth?". mHealth Intelligence. Retrieved 19 October 2016.
  13. ↑ Dignan L (18 November 2015). "Ready for digital therapeutics? Andreessen Horowitz hopes so". ZDNet. Archived from the original on November 19, 2015. Retrieved 19 October 2016.
  14. 1 2 Pinto MD, Greenblatt AM, Hickman RL, Rice HM, Thomas TL, Clochesy JM (July 2016). "Assessing the Critical Parameters of eSMART-MH: A Promising Avatar-Based Digital Therapeutic Intervention to Reduce Depressive Symptoms". Perspectives in Psychiatric Care. 52 (3): 157–168. doi: 10.1111/ppc.12112 . PMID   25800698.
  15. 1 2 3 4 Lorenzetti L (22 April 2016). "This Company Is Tackling Diabetes With 'Digital Therapeutics'". Fortune . Retrieved 19 October 2016.
  16. 1 2 3 Elliott WJ, Izzo JL (August 2006). "Device-guided breathing to lower blood pressure: case report and clinical overview". MedGenMed. 8 (3): 23. PMC   1781326 . PMID   17406163.
  17. 1 2 Baum S (30 April 2016). "Digitizing substance abuse treatment and recovery". Med City News. Retrieved 19 October 2016.
  18. 1 2 3 Gebremedhin D, Schuster M (29 August 2016). "Overview: Health tech startups innovating the behavioral health space". Mobi Health News. Retrieved 19 October 2016.
  19. ↑ Honeyman M, Gretton C (15 April 2016). "Eight technologies that could change healthcare beyond recognition". The Guardian . Retrieved 19 October 2016.
  20. 1 2 Suennen L (29 March 2016). "Is the time right for digital therapeutics?". Med City News. Retrieved 19 October 2016.
  21. ↑ Yeager D (November 2014). "Fighting Chronic Disease With Digital Therapeutics". Today's Dietitian. Retrieved 19 October 2016.
  22. ↑ "TEAS Plus Trademark Application". United States Patent and Trademark Office. 27 October 2012. 85765357.
  23. 1 2 Le Ber JM, Lombardo NT, Wimmer E (22 January 2015). "Building technology services that address student needs". Medical Reference Services Quarterly. 34 (1): 1–16. doi:10.1080/02763869.2015.986708. PMID   25611437. S2CID   21795716.
  24. ↑ "Digital Therapeutics Alliance".
  25. 1 2 Kvedar J (25 August 2016). "It's time to break free of the traditional paradigms of disease management". Med City News. Retrieved 19 October 2016.
  26. 1 2 3 Willey S, Walsh JK (January 2016). "Outcomes of a Mobile Health Coaching Platform: 12-Week Results of a Single-Arm Longitudinal Study". JMIR mHealth and uHealth. 4 (1): e3. doi: 10.2196/mhealth.4933 . PMC   4723727 . PMID   26747611.
  27. ↑ Walsh KM, Saab BJ, Farb NA (January 2019). "Effects of a Mindfulness Meditation App on Subjective Well-Being: Active Randomized Controlled Trial and Experience Sampling Study". JMIR Mental Health. 6 (1): e10844. doi: 10.2196/10844 . PMC   6329416 . PMID   30622094.
  28. ↑ Gensorowsky, Daniel; Witte, Julian; Batram, Manuel; Greiner, Wolfgang (December 2022). "Market access and value-based pricing of digital health applications in Germany". Cost Effectiveness and Resource Allocation. 20 (1): 25. doi: 10.1186/s12962-022-00359-y . ISSN   1478-7547. PMC   9195309 . PMID   35698135.
  29. 1 2 van Kessel, Robin; Roman-Urrestarazu, Andres; Anderson, Michael; Kyriopoulos, Ilias; Field, Samantha; Monti, Giovanni; Reed, Shelby D; Pavlova, Milena; Wharton, George; Mossialos, Elias (2023-07-25). "Mapping Factors That Affect the Uptake of Digital Therapeutics Within Health Systems: Scoping Review". Journal of Medical Internet Research. 25: e48000. doi: 10.2196/48000 . ISSN   1438-8871. PMC   10410406 . PMID   37490322.
  30. ↑ Lantzsch, Hendrikje; Panteli, Dimitra; Martino, Filippo; Stephani, Victor; Seißler, David; Püschel, Constanze; Knöppler, Karsten; Busse, Reinhard (2022-04-21). "Benefit Assessment and Reimbursement of Digital Health Applications: Concepts for Setting Up a New System for Public Coverage". Frontiers in Public Health. 10: 832870. doi: 10.3389/fpubh.2022.832870 . ISSN   2296-2565. PMC   9068958 . PMID   35530738.
  31. ↑ Haig, Madeleine; Main, Caitlin; Chávez, Danitza; Kanavos, Panos (June 2023). "A Value Framework to Assess Patient-Facing Digital Health Technologies That Aim to Improve Chronic Disease Management: A Delphi Approach". Value in Health. doi: 10.1016/j.jval.2023.06.008 . PMID   37385445.
  32. ↑ Wicks P, Chiauzzi E (September 2015). "'Trust but verify'--five approaches to ensure safe medical apps". BMC Medicine. 13 (1): 205. doi: 10.1186/s12916-015-0451-z . PMC   4583172 . PMID   26404791.
  33. 1 2 Miao BY, Arneson D, Wang M, Butte AJ (January 2022). Celi LA (ed.). "Open challenges in developing digital therapeutics in the United States". PLOS Digital Health. 1 (1): e0000008. doi: 10.1371/journal.pdig.0000008 . ISSN   2767-3170. PMC   9931293 . PMID   36812515.
  34. ↑ Stern, Ariel Dora; Gordon, William J; Landman, Adam B; Kramer, Daniel B (June 2019). "Cybersecurity features of digital medical devices: an analysis of FDA product summaries". BMJ Open. 9 (6): e025374. doi:10.1136/bmjopen-2018-025374. ISSN   2044-6055. PMC   6609083 . PMID   31256020.
  35. 1 2 3 Reuter E (11 April 2022). "Can digital therapeutics become profitable?". MedTech Dive. Retrieved 2023-01-29.
  36. ↑ Patel N. "Medicare Billing Codes For Digital Therapeutics: A Path Forward". Health Affairs Forefront.
  37. ↑ Foxon G, Danev V, Craddy P, Wilson C (January 2022). "POSA263 How Do the Pricing and Reimbursement Policies for Digital Therapeutics Compare and Contrast Between the US, EU-5, China and Japan?". Value in Health. 25 (1): S171. doi: 10.1016/j.jval.2021.11.830 . S2CID   246150970.
  38. ↑ Dahlhausen F, Zinner M, Bieske L, Ehlers JP, Boehme P, Fehring L (January 2022). "There's an app for that, but nobody's using it: Insights on improving patient access and adherence to digital therapeutics in Germany". Digital Health. 8: 20552076221104672. doi:10.1177/20552076221104672. PMC   9260569 . PMID   35811758.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.